Maria Fardis

Chief Executive Officer at AirNexis Therapeutics.

Raised on AirNexis Therapeutics filings

$62M

of $200M offered across 1 Form D filing

Company

Biotech · Palo Alto, CA

Inhaled PDE3/4 inhibitor for COPD maintenance

Inhaled PDE3/4 inhibitor for COPD maintenance

AirNexis Therapeutics Form D filings
Filed	Security	Sold of offered	Filing
Mar 9, 2026	Equity	$62M/ $200M	Form D

Also named on AirNexis Therapeutics filings